• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

作为用于基于树突状细胞的疫苗开发的抗原递送纳米平台的核黄素合酶蛋白笼状纳米颗粒。

Lumazine synthase protein cage nanoparticles as antigen delivery nanoplatforms for dendritic cell-based vaccine development.

作者信息

Ra Jae-Sun, Shin Hyun-Hee, Kang Sebyung, Do Yoonkyung

机构信息

School of Life Sciences, Ulsan National Institute of Science and Technology, Ulsan, Korea.

出版信息

Clin Exp Vaccine Res. 2014 Jul;3(2):227-34. doi: 10.7774/cevr.2014.3.2.227. Epub 2014 Jun 20.

DOI:10.7774/cevr.2014.3.2.227
PMID:25003097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4083076/
Abstract

PURPOSE

Protein cages are promising nanoplatform candidates for efficient delivery systems due to their homogenous size and structure with high biocompatibility and biodegradability. In this study, we investigate the potential of lumazine synthase protein cage as an antigen delivery system to dendritic cells (DCs), which induce antigen-specific T cell proliferation.

MATERIALS AND METHODS

Ovalbumin (OVA) peptides OT-1 (SIINFEKL) and OT-2 (ISQAVHAAHAEINEAGR) were genetically inserted to lumazine synthase and each protein cage was over-expressed in Escherichia coli as a soluble protein. The efficiency of antigen delivery and the resulting antigen-specific T cell proliferation by DCs was examined in vitro as well as in vivo.

RESULTS

We successfully generated and characterized OVA peptides carrying lumazine synthase protein cages. The OT-1 and OT-2 peptides carried by lumazine synthases were efficiently delivered and processed by DCs in vitro as well as in vivo, and induced proliferation of OT-1-specific CD8(+)T cells and OT-2-specific CD4(+)T cells.

CONCLUSION

Our data demonstrate the potential of lumazine synthase protein cage being used as a novel antigen delivery system for DC-based vaccine development in future clinical applications.

摘要

目的

蛋白质笼因其尺寸和结构均一，具有高生物相容性和可生物降解性，是高效递送系统中很有前景的纳米平台候选物。在本研究中，我们探究了核黄素合酶蛋白质笼作为抗原递送至树突状细胞（DCs）的潜力，树突状细胞可诱导抗原特异性T细胞增殖。

材料与方法

将卵清蛋白（OVA）肽OT-1（SIINFEKL）和OT-2（ISQAVHAAHAEINEAGR）通过基因工程插入核黄素合酶，每种蛋白质笼在大肠杆菌中作为可溶性蛋白过表达。在体外和体内检测了DCs的抗原递送效率以及由此产生的抗原特异性T细胞增殖情况。

结果

我们成功制备并表征了携带核黄素合酶蛋白质笼的OVA肽。核黄素合酶携带的OT-1和OT-2肽在体外和体内均能被DCs有效递送和加工，并诱导OT-1特异性CD8(+)T细胞和OT-2特异性CD4(+)T细胞增殖。

结论

我们的数据证明了核黄素合酶蛋白质笼在未来临床应用中作为基于DC的疫苗开发的新型抗原递送系统的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0796/4083076/bdafa8c8e896/cevr-3-227-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0796/4083076/7aebd76fe2ae/cevr-3-227-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0796/4083076/772ac2754ef8/cevr-3-227-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0796/4083076/8761cf36ff87/cevr-3-227-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0796/4083076/de634ee4cc2f/cevr-3-227-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0796/4083076/bdafa8c8e896/cevr-3-227-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0796/4083076/7aebd76fe2ae/cevr-3-227-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0796/4083076/772ac2754ef8/cevr-3-227-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0796/4083076/8761cf36ff87/cevr-3-227-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0796/4083076/de634ee4cc2f/cevr-3-227-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0796/4083076/bdafa8c8e896/cevr-3-227-g005.jpg

相似文献

1
Lumazine synthase protein cage nanoparticles as antigen delivery nanoplatforms for dendritic cell-based vaccine development.作为用于基于树突状细胞的疫苗开发的抗原递送纳米平台的核黄素合酶蛋白笼状纳米颗粒。
Clin Exp Vaccine Res. 2014 Jul;3(2):227-34. doi: 10.7774/cevr.2014.3.2.227. Epub 2014 Jun 20.
2
Ferritin protein cage nanoparticles as versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development.铁蛋白蛋白笼纳米颗粒作为多功能抗原递呈纳米平台，用于树突状细胞（DC）为基础的疫苗开发。
Nanomedicine. 2014 Apr;10(3):561-9. doi: 10.1016/j.nano.2013.11.003. Epub 2013 Nov 18.
3
Effective Delivery of Antigen-Encapsulin Nanoparticle Fusions to Dendritic Cells Leads to Antigen-Specific Cytotoxic T Cell Activation and Tumor Rejection.抗原-包裹体纳米颗粒融合物的有效递送至树突状细胞导致抗原特异性细胞毒性 T 细胞激活和肿瘤排斥。
ACS Nano. 2016 Aug 23;10(8):7339-50. doi: 10.1021/acsnano.5b08084. Epub 2016 Jul 13.
4
Simultaneous in vivo tracking of dendritic cells and priming of an antigen-specific immune response.体内同时追踪树突状细胞和引发抗原特异性免疫反应。
Biomaterials. 2011 Sep;32(26):6254-63. doi: 10.1016/j.biomaterials.2011.05.013. Epub 2011 May 26.
5
Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation.聚(丙硫醚)纳米粒子通过二硫键连接的肽向树突状细胞传递抗原：交叉呈递和 T 细胞激活。
Vaccine. 2010 Nov 23;28(50):7897-906. doi: 10.1016/j.vaccine.2010.09.077. Epub 2010 Oct 8.
6
Protein Cage Nanoparticles as Delivery Nanoplatforms.蛋白质笼纳米颗粒作为递药纳米平台。
Adv Exp Med Biol. 2018;1064:27-43. doi: 10.1007/978-981-13-0445-3_2.
7
ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.免疫刺激复合物佐剂在体内将免疫激活与抗原递呈给树突状细胞相结合，从而有效诱导 CD8+ T 细胞的交叉呈递。
J Immunol. 2011 Jul 1;187(1):55-63. doi: 10.4049/jimmunol.1004114. Epub 2011 May 25.
8
Asymmetric Assembly and Self-Adjuvanted Antigen Delivery Platform for Improved Antigen Uptake and Antitumor Effect.用于改善抗原摄取和抗肿瘤效果的不对称组装及自佐剂抗原递送平台
Bioconjug Chem. 2023 May 17;34(5):856-865. doi: 10.1021/acs.bioconjchem.3c00060. Epub 2023 Apr 21.
9
Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles.通过在聚（D，L-乳酸-共-乙醇酸）纳米颗粒中共同递送卵清蛋白和 Toll 样受体配体单磷酰脂质 A 增强抗原特异性初始 CD4+ 和 CD8+ 反应。
J Biomed Mater Res A. 2007 Jun 1;81(3):652-62. doi: 10.1002/jbm.a.31019.
10
A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules.利用纳米工程聚合物水凝胶胶囊进行体内 T 细胞刺激的保护性疫苗输送系统。
ACS Nano. 2009 Nov 24;3(11):3391-400. doi: 10.1021/nn900715g.

引用本文的文献

1
Protein nanocages: A new frontier in mucosal vaccine delivery and immune activation.蛋白质纳米笼：黏膜疫苗递送与免疫激活的新前沿。
Hum Vaccin Immunother. 2025 Dec;21(1):2492906. doi: 10.1080/21645515.2025.2492906. Epub 2025 May 12.
2
Nano Approaches to Nucleic Acid Delivery: Barriers, Solutions, and Current Landscape.核酸递送的纳米方法：障碍、解决方案及当前态势
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025 Mar-Apr;17(2):e70010. doi: 10.1002/wnan.70010.
3
Opportunities and challenges of mRNA technologies in development of dengue virus vaccine.

本文引用的文献

1
Fabrication of uniform layer-by-layer assemblies with complementary protein cage nanobuilding blocks via simple His-tag/metal recognition.通过简单的组氨酸标签/金属识别，利用互补蛋白质笼纳米构建块制备均匀的逐层组装体。
J Mater Chem B. 2013 Sep 21;1(35):4504-4510. doi: 10.1039/c3tb20554a. Epub 2013 Jul 29.
2
Ferritin protein cage nanoparticles as versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development.铁蛋白蛋白笼纳米颗粒作为多功能抗原递呈纳米平台，用于树突状细胞（DC）为基础的疫苗开发。
Nanomedicine. 2014 Apr;10(3):561-9. doi: 10.1016/j.nano.2013.11.003. Epub 2013 Nov 18.
3
Implementation of P22 viral capsids as intravascular magnetic resonance T1 contrast conjugates via site-selective attachment of Gd(III)-chelating agents.
信使核糖核酸技术在登革病毒疫苗研发中的机遇与挑战
Front Immunol. 2025 Mar 5;16:1520968. doi: 10.3389/fimmu.2025.1520968. eCollection 2025.
4
Manufacturing of non-viral protein nanocages for biotechnological and biomedical applications.用于生物技术和生物医学应用的非病毒蛋白质纳米笼的制造。
Front Bioeng Biotechnol. 2023 Jul 13;11:1200729. doi: 10.3389/fbioe.2023.1200729. eCollection 2023.
5
A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529).一种多价且热稳定的纳米抗体中和 SARS-CoV-2 奥密克戎（B.1.1.529）。
Int J Nanomedicine. 2023 Jan 19;18:353-367. doi: 10.2147/IJN.S387160. eCollection 2023.
6
Genetically Encoded Self-Assembling Protein Nanoparticles for the Targeted Delivery In Vitro and In Vivo.用于体外和体内靶向递送的基因编码自组装蛋白质纳米颗粒。
Pharmaceutics. 2023 Jan 10;15(1):231. doi: 10.3390/pharmaceutics15010231.
7
Biological Nanoparticles in Vaccine Development.疫苗研发中的生物纳米颗粒。
Front Bioeng Biotechnol. 2022 Mar 23;10:867119. doi: 10.3389/fbioe.2022.867119. eCollection 2022.
8
Soluble overexpression and purification of infectious bursal disease virus capsid protein VP2 in and its nanometer structure observation.在 和 中可溶性过表达和纯化传染性法氏囊病病毒衣壳蛋白 VP2 及其纳米结构观察。
Cell Cycle. 2022 Jul;21(14):1532-1542. doi: 10.1080/15384101.2022.2056305. Epub 2022 Mar 28.
9
Application of periostin peptide-decorated self-assembled protein cage nanoparticles for therapeutic angiogenesis.外泌体载姜黄素前体脂质体凝胶的制备及其体内评价
BMB Rep. 2022 Apr;55(4):175-180. doi: 10.5483/BMBRep.2022.55.4.137.
10
Development of a Modular Vaccine Platform for Multimeric Antigen Display Using an Orthobunyavirus Model.使用正布尼亚病毒模型开发用于多聚体抗原展示的模块化疫苗平台。
Vaccines (Basel). 2021 Jun 15;9(6):651. doi: 10.3390/vaccines9060651.
通过对 Gd(III)螯合剂进行位点选择性连接，将 P22 病毒衣壳作为血管内磁共振 T1 对比剂偶联物。
Biomacromolecules. 2013 Jul 8;14(7):2332-9. doi: 10.1021/bm400461j. Epub 2013 Jun 24.
4
Incorporation of thrombin cleavage peptide into a protein cage for constructing a protease-responsive multifunctional delivery nanoplatform.将凝血酶切割肽整合到蛋白质笼中，构建一种蛋白酶响应型多功能递药纳米平台。
Biomacromolecules. 2012 Dec 10;13(12):4057-64. doi: 10.1021/bm301339s. Epub 2012 Nov 29.
5
Developing an antibody-binding protein cage as a molecular recognition drug modular nanoplatform.研发一种抗体结合蛋白笼作为分子识别药物的模块化纳米平台。
Biomaterials. 2012 Jul;33(21):5423-30. doi: 10.1016/j.biomaterials.2012.03.055. Epub 2012 Apr 28.
6
Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.针对非突变肿瘤抗原 HER2/neu 靶向成熟树突状细胞可诱导整合免疫反应，从而保护小鼠免受乳腺癌的侵害。
Breast Cancer Res. 2012 Mar 7;14(2):R39. doi: 10.1186/bcr3135.
7
Efficient in vitro encapsulation of protein cargo by an engineered protein container.通过工程化蛋白质容器高效体外包封蛋白质货物。
J Am Chem Soc. 2012 Jan 18;134(2):909-11. doi: 10.1021/ja211011k. Epub 2012 Jan 3.
8
Decisions about dendritic cells: past, present, and future.关于树突状细胞的决策：过去、现在和未来。
Annu Rev Immunol. 2012;30:1-22. doi: 10.1146/annurev-immunol-100311-102839. Epub 2011 Nov 17.
9
Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity.树突状细胞靶向蛋白疫苗：诱导 T 细胞免疫的一种新方法。
J Intern Med. 2012 Feb;271(2):183-92. doi: 10.1111/j.1365-2796.2011.02496.x. Epub 2012 Jan 4.
10
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates.针对树突状细胞的 HIV Gag 免疫接种，继之以重组纽约痘苗病毒，可在非人灵长类动物中诱导强烈的 T 细胞免疫应答。
Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7131-6. doi: 10.1073/pnas.1103869108. Epub 2011 Apr 5.